# AAVantgarde Bio

> AAVantgarde Bio is a clinical-stage biotechnology company in Milan, Italy, developing
> dual-vector AAV gene therapies for inherited retinal diseases. It publishes no public
> API, developer program, SDK or machine-readable contract. This file is generated by
> API Evangelist from an independent third-party profile; it is not published by
> AAVantgarde and does not describe an API, because there is not one.

Generated: 2026-09-05
Method: generated
Source: apis.yml and the artifacts in this repository, plus probes of www.aavantgarde.com on 2026-09-05
Note: AAVantgarde does not serve /llms.txt (probed https://www.aavantgarde.com/llms.txt -> HTTP 404).

## What this company is

- Clinical-stage gene therapy company, founded 2021 by Prof. Alberto Auricchio, headquartered in Milan, Italy.
- Two proprietary AAV vector platforms — dual hybrid and dual intein — that split a large
  expression cassette across two AAV8 vectors so it can exceed single-vector cargo capacity.
- AAVB-081: dual hybrid AAV therapy for retinitis pigmentosa due to Usher syndrome type 1B
  (MYO7A). LUCE-1 Phase 1/2; the first dual AAV gene therapy tested clinically in an ocular indication.
- AAVB-039: dual intein AAV therapy for ABCA4-associated Stargardt disease. CELESTE Phase 1/2;
  FDA Fast Track and Orphan Drug designation.
- STELLA: natural history study.
- Funding: EUR 61 million Series A, USD 141 million Series B.

## API surface

- No public API. No developer portal, no API reference, no OpenAPI/AsyncAPI/GraphQL/gRPC/WSDL contract.
- No MCP server, no A2A agent card, no SDK or package on npm, PyPI, RubyGems, crates.io, NuGet, Maven or pkg.go.dev.
- No GitHub organization (api.github.com/orgs/aavantgarde, /aavantgardebio, /aavantgarde-bio all HTTP 404).
- No api., developer., docs., status. or trust. subdomain (all NXDOMAIN).

## Machine-readable documents that ARE served

- https://www.aavantgarde.com/.well-known/openid-configuration (200) — OpenID Connect discovery
  for the corporate website's Umbraco CMS *member* authentication, not a developer API.
- https://www.aavantgarde.com/.well-known/jwks (200) — the signing key set named by the above.
- https://www.aavantgarde.com/.well-known/security.txt (200) — RFC 9116, but EXPIRED (2026-01-01)
  and its Contact is the web agency that built the site.

## Company pages

- Home: https://www.aavantgarde.com/en/
- About: https://www.aavantgarde.com/en/about/
- Innovation and technology: https://www.aavantgarde.com/en/innovation/
- Pipeline: https://www.aavantgarde.com/en/innovation/pipeline/
- Clinical trials: https://www.aavantgarde.com/en/clinical-trials/
- For patients: https://www.aavantgarde.com/en/for-patients/
- News: https://www.aavantgarde.com/en/news/
- Careers: https://www.aavantgarde.com/en/careers/
- Contact: https://www.aavantgarde.com/en/contact/
- Privacy notice: https://www.aavantgarde.com/en/privacy-notice/
- LinkedIn: https://www.linkedin.com/company/aavantgarde-bio

## Artifacts in this profile

- well-known/aavantgardebio-well-known.yml — probe index for every RFC 8615 path, per host.
- conformance/aavantgardebio-conformance.yml — OIDC/OAuth2/JWKS/security.txt findings.
- security/aavantgardebio-domain-security.yml — TLS, HSTS, DNSSEC, CAA, SPF, DMARC.
- security/aavantgardebio-vulnerability-disclosure.yml — why the served security.txt is not a program.